Tuesday, October 29, 2019

October 29, 2019 at 03:41PM Hizentra

Product approval information is indicated for treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2PutKXo

No comments:

Post a Comment